Screening data from major randomized controlled trials like The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP), The European Randomised Study of Screening for Prostate Cancer (ERSPC), The Prostate, Lung, Colorectal and Ovarian (PLCO), with a screening group and a control group, over 10 years, showed that for every 1000 people, two patients from the screening group will die of PCa. Here, KLK3 is linked to prostate cancer.